Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 367

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS

Johnson, Philip C., Wheat, L. Joseph, Cloud, Gretchen A., Goldman, Mitchell, Lancaster, Dan, Bamberger, David M., Powderly, William G., Hafner, Richard, Kauffman, Carol A., Dismukes, William E., for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group* · 2002 · Annals of Internal Medicine

Abstract

BACKGROUND: In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with use of amphotericin B. OBJECTIVE: To compare amphotericin B with liposomal amphotericin B for induction therapy of moderate to severe disseminated histoplasmosis in patients with AIDS. DESIGN: Randomized, double-blind, multicenter clinical trial. SETTING: 21 sites of the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. PATIENTS: 81 patients with AIDS and moderate to severe disseminated histoplasmosis. MEASUREMENTS: Clinical success, conversion of baseline blood cultures to negative, and acute toxicities that necessitated discontinuation of treatment. RESULTS: Clinical success was achieved in 14 of 22 patients (64%) treated with amphotericin B compared with 45 of 51 patients (88%) receiving liposomal amphotericin B (difference, 24 percentage points [95% CI, 1 to 52 percentage points]). Culture conversion rates were similar. Three patients treated with amphotericin B and one treated with liposomal amphotericin B died during induction (P = 0.04). Infusion-related side effects were greater with amphotericin B (63%) than with liposomal amphotericin B (25%) (P = 0.002). Nephrotoxicity occurred in 37% of patients treated with amphotericin B and 9% of patients treated with liposomal amphotericin B (P = 0.003). CONCLUSION: Liposomal amphotericin B seems to be a less toxic alternative to amphotericin B and is associated with improved survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-137-2-200207160-00008

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 367

Metadata

Authors
Johnson, P. C., Wheat, L. J., Cloud, G. A., Goldman, M., Lancaster, D., Bamberger, D. M., Powderly, W. G., Hafner, R., Kauffman, C. A., Dismukes, W. E., & for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group*
Venue
Annals of Internal Medicine
Published
2002-07-16
Volume
137
Issue
2
Pages
105-109
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2117574372
Cited by
367
References
19
FWCI
9.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. https://app.cochat.ai/papers/10.7326/0003-4819-137-2-200207160-00008
The paper
Johnson, P. C., Wheat, L. J., Cloud, G. A., Goldman, M., Lancaster, D., Bamberger, D. M., Powderly, W. G., Hafner, R., Kauffman, C. A., Dismukes, W. E., & for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group*. (2002). Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-137-2-200207160-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.